From the Department of Anaesthesiology and Perioperative Medicine, Alfred Hospital and Monash University, Melbourne, Australia.
Department of Anaesthesia, Austin Hospital, Melbourne, Australia.
Anesth Analg. 2022 Feb 1;134(2):410-418. doi: 10.1213/ANE.0000000000005811.
Prevention of hypotension during the intra- and postoperative period is an important goal. Peripheral administration of low-concentration norepinephrine may be a safe and effective strategy to reduce the risk of hypotension.
We conducted a 2-center, randomized pilot feasibility trial, with a target of 60 adult patients undergoing major noncardiac surgery. We randomized patients to receive a peripheral low-concentration (10 µg/mL) norepinephrine or placebo (saline 0.9%) infusion. The study drug infusion was titrated to achieve a minimum systolic blood pressure target, preselected within 10% of baseline value and within the range limit 100 to 120 mm Hg during surgery and for up to 4 or 24 hours postoperatively.
We achieved a high consent rate (84%), successful study drug administration throughout surgery (98% of patients) and absence of unblinding. There were no important study drug-related adverse events. The average intraoperative systolic blood pressure was 120 ± 12.6 mm Hg in the norepinephrine group and 115 ± 14.9 mm Hg in the placebo group. The mean difference between the intraoperative systolic blood pressure achieved less the preselected minimum systolic blood pressure target was 10.0 ± 12.7 mm Hg in the norepinephrine group and 2.9 ± 14.7 mm Hg in the placebo group; difference in means, 7.1 (95% confidence interval, 0.2-14.0) mm Hg.
A future large trial evaluating the effectiveness and safety of peripheral administration of low-concentration norepinephrine during the perioperative period is feasible, and likely to achieve a minimum systolic blood pressure threshold.
预防围术期低血压是一个重要目标。外周给予低浓度去甲肾上腺素可能是降低低血压风险的安全有效策略。
我们开展了一项 2 中心、随机、初步可行性试验,纳入了 60 名接受非心脏大手术的成年患者。我们将患者随机分为外周输注低浓度(10μg/ml)去甲肾上腺素或安慰剂(生理盐水 0.9%)组。研究药物输注滴定以达到术中最小收缩压目标,该目标在基线值的 10%范围内预先选定,且收缩压范围限制在 100 至 120mmHg 之间,持续至术后 4 小时或 24 小时。
我们获得了高的同意率(84%),术中(98%的患者)成功给予了研究药物且未发生揭盲。没有与研究药物相关的重要不良事件。去甲肾上腺素组术中平均收缩压为 120 ± 12.6mmHg,安慰剂组为 115 ± 14.9mmHg。去甲肾上腺素组术中收缩压与预先选定的最小收缩压目标之间的平均差值为 10.0 ± 12.7mmHg,安慰剂组为 2.9 ± 14.7mmHg;差值的均值为 7.1mmHg(95%置信区间,0.2-14.0mmHg)。
评估围术期外周给予低浓度去甲肾上腺素的有效性和安全性的未来大型试验是可行的,且可能达到最小收缩压阈值。